Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.17.20 - Carboxypeptidase U

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Levels of thrombin-activatable fibrinolysis inhibitor and platelet-activating factor in recurrent pregnancy loss patients.
Reduced plasma fibrinolytic potential in patients with recurrent implantation failure after IVF and embryo transfer.
Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with recurrent miscarriage.
Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Abortion, Spontaneous
Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion.
The prevalence of combined vascular endothelial growth factor, endothelial nitric oxide synthase and thrombin-activatable fibrinolysis inhibitor genetic polymorphisms among Egyptian patients with recurrent spontaneous abortion.
Thrombin-Activatable Fibrinolysis Inhibitor Gene Polymorphism (TAFI1040C/T) in Women With Recurrent Spontaneous Abortion.
Activated Protein C Resistance
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Acute Coronary Syndrome
Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome.
Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.
Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
Acute Lung Injury
Thrombin-Activatable Fibrinolysis Inhibitor Protects against Acute Lung Injury by Inhibiting the Complement System.
Adenocarcinoma
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Amyloidosis
Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
Angina, Stable
Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG).
Angina, Unstable
Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
Angioedema
Angioedema. A review on the acquired, allergic or non-allergic, and the hereditary forms.
Antiphospholipid Syndrome
Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.
Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Aortic Aneurysm, Abdominal
Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm.
Enhanced Abdominal Aortic Aneurysm Formation in Thrombin-Activatable Procarboxypeptidase B-Deficient Mice.
Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
Arthritis
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.
Arthritis, Rheumatoid
An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis.
Assessment of hemostatic disturbances in women with established rheumatoid arthritis.
Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis.
Asthma
Role of Thrombin-Activatable Fibrinolysis Inhibitor in Allergic Bronchial Asthma.
Up-regulation of the extrinsic coagulation pathway in acute asthma--a case study.
[Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients]
Atherosclerosis
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes.
Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Atypical Hemolytic Uremic Syndrome
Thrombomodulin mutations in atypical hemolytic-uremic syndrome.
Bacterial Infections
EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats.
beta-Thalassemia
Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
Breast Neoplasms
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.
Data supporting the structural and functional characterization of Thrombin-Activatable Fibrinolysis Inhibitor in breast cancer.
Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Thrombin-activatable fibrinolysis inhibitor in breast cancer patients.
Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
carboxypeptidase u deficiency
Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
Procarboxypeptidase R deficiency causes increased lethality in concanavalin A-induced hepatitis in female mice.
Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
Carcinogenesis
The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer.
Carcinoma
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Carcinoma, Hepatocellular
Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells.
Molecular Mechanism Underlying the Suppression of CPB2 Expression Caused by Persistent Hepatitis C Virus RNA Replication.
PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells.
Carcinoma, Small Cell
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Carcinoma, Squamous Cell
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Cardiovascular Diseases
A new functional assay of thrombin activatable fibrinolysis inhibitor.
Clots, kinins and coronaries.
Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.
Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
Cerebral Infarction
Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population.
coagulation factor xia deficiency
Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency.
Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects.
Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Colitis, Ulcerative
Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis.
Corneal Neovascularization
The role of the fibrinolytic system in corneal angiogenesis.
Coronary Artery Disease
Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Changes in ADMA and TAFI levels after stenting in coronary artery disease patients.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.
Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG).
Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
Coronary Disease
Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
[Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease]
Coronary Restenosis
Changes in ADMA and TAFI levels after stenting in coronary artery disease patients.
Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
COVID-19
Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.
Cushing Syndrome
Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Diabetes Mellitus
Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease.
Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications.
Polycystic ovary syndrome: clinical and laboratory variables related to new phenotypes using machine-learning models.
Predisposing factors to post-operative adhesion development.
Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
Diabetes Mellitus, Type 1
Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications.
Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state.
Diabetes Mellitus, Type 2
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Diabetes, Gestational
Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus.
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes.
Diabetic Foot
Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.
Diabetic Nephropathies
Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients.
Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy.
Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Disseminated Intravascular Coagulation
A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase.
Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
Dyslipidemias
Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia.
Endometriosis
Genetic Variants in Fibrinolytic System-Related Genes in Infertile Women With and Without Endometriosis.
Endotoxemia
Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia.
Factor XI Deficiency
Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency.
Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects.
Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Factor XIII Deficiency
Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency.
Familial Mediterranean Fever
Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
Fatty Liver
Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Foot Ulcer
Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.
Glioblastoma
Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.
Glomerulonephritis
EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis.
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
Glucose Intolerance
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes.
Hashimoto Disease
The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis.
Heart Failure
A Prothrombotic State in Patients With a History of Left Ventricular Thrombus.
Hemophilia A
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients.
Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
TAFI made stickier.
Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.
Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
Hemophilia B
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Hemorrhagic Fever, Crimean
Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever.
Hepatitis
Hepatitis induced by an IgM monoclonal antibody against procarboxypeptidase R.
Procarboxypeptidase R deficiency causes increased lethality in concanavalin A-induced hepatitis in female mice.
Hyperalgesia
Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
Hypercholesterolemia
Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Hyperglycemia
Predisposing factors to post-operative adhesion development.
Hyperlipidemias
Development of ELISAs measuring the extent of TAFI activation.
Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
Hyperparathyroidism, Primary
Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Hypertension
The relationship among TAFI, t-PA, PAI-1 and F1?+?2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
Hypertension, Pregnancy-Induced
Thrombin activatable fibrinolysis inhibitor in preeclampsia and gestational hypertension throughout the gestation.
Hypertension, Pulmonary
Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
Hyperthyroidism
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Hypotension
Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy.
Hypothyroidism
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
Infections
Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
Inflammatory Bowel Diseases
Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Plasma levels of thrombin activatable fibrinolysis inhibitor antigen in active and inactive inflammatory bowel disease.
Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Inflammatory Breast Neoplasms
IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Influenza, Human
Characterization of the carboxypeptidase involved in the proteolytic cleavage of the influenza haemagglutinin.
Insulin Resistance
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.
Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus?
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes.
Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome.
Intracranial Hemorrhages
Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
Ischemic Stroke
Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy.
Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.
Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome.
Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.
Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke.
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
Kidney Failure, Chronic
Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients.
Serum procarboxypeptidase B, amylase and lipase in chronic renal failure.
Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Liver Diseases
Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
Lung Diseases, Interstitial
Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease.
Lung Neoplasms
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Lupus Erythematosus, Systemic
Thrombin-activatable fibrinolysis inhibitor and activated factor XII in patients with systemic lupus erythematosus.
Meningitis, Pneumococcal
Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
Meningococcal Infections
A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
Metabolic Syndrome
Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome.
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Predisposing factors to post-operative adhesion development.
Mouth Neoplasms
The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer.
Multiple Myeloma
Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma.
Muscle Cramp
Knowledge, attitude and practice towards anthrax in northern Ethiopia: a mixed approach study.
Myocardial Infarction
Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
Structures of potent selective peptide mimetics bound to carboxypeptidase B.
Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
[Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis.]
Nasal Polyps
Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.
Neoplasm Metastasis
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Neoplasms
Biochemical analysis of secretory proteins synthesized by normal rat pancreas and by pancreatic acinar tumor cells.
Comparison of secretory protein profiles in developing rat pancreatic rudiments and rat acinar tumor cells.
Endothelial function and novel adhesion molecule CD44 in kidney allograft recipients.
High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double deficient mice.
IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Predisposing factors to post-operative adhesion development.
Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism.
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Nephrotic Syndrome
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Obesity
Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Predisposing factors to post-operative adhesion development.
Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6?months after obesity surgery.
[The role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in obesity]
Overweight
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Pancreatitis
A study on the activation peptide released from procarboxypeptidase B (CAPAP) and anionic trypsinogen in patients with acute abdominal disorders of non-pancreatic origin.
Activation peptide of carboxypeptidase B in serum and urine in acute pancreatitis.
Active carboxypeptidase B is present in free form in serum from patients with acute pancreatitis.
Comparative analysis of the sequences and three-dimensional models of human procarboxypeptidases A1, A2 and B.
Isolation of a cDNA encoding a human serum marker for acute pancreatitis. Identification of pancreas-specific protein as pancreatic procarboxypeptidase B.
Laboratory markers of severe acute pancreatitis.
Monocyte Chemoattractant Protein 1, Active Carboxypeptidase B and CAPAP at Hospital Admission Are Predictive Markers for Severe Acute Pancreatitis.
Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis.
Protease Activation, Pancreatic Leakage, and Inflammation in Acute Pancreatitis: Differences between Mild and Severe Cases and Changes over the First Three Days.
Radioimmunoassay of active pancreatic enzymes in sera from patients with acute pancreatitis. I. Active carboxypeptidase B.
Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic diseases.
Serum procarboxypeptidase B, amylase and lipase in chronic renal failure.
The clinical value of human pancreas-specific protein procarboxypeptidase B as an indicator of necrosis in acute pancreatitis: comparison to CRP and LDH.
Thrombin activatable fibrinolysis inhibitor as an indicator of the severity of acute pancreatitis.
Pancreatitis, Acute Necrotizing
Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic diseases.
Peripheral Arterial Disease
High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease.
Polycystic Ovary Syndrome
Effect of android fat distribution on thrombin-activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Thrombin-Activatable Fibrinolysis Inhibitor and Cardiovascular Risk Factors in Polycystic Ovary Syndrome.
Postthrombotic Syndrome
Novel antithrombotic strategies for treatment of venous thromboembolism.
Pre-Eclampsia
Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia.
Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
Fibrinolysis parameters in Sudanese women with severe preeclampsia.
Preeclampsia and its interaction with common variants in thrombophilia genes.
Thrombin activatable fibrinolysis inhibitor in preeclampsia and gestational hypertension throughout the gestation.
protein-glutamine gamma-glutamyltransferase deficiency
Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency.
Pulmonary Embolism
Association of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism.
Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism.
S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism.
[Spontaneous fibrinolysis and possibilities of its acceleration in pulmonary embolism].
Respiratory Distress Syndrome
Thrombin activatable fibrinolysis inhibitor activity, thrombin-antithrombin complex and D-dimer levels in preterm neonates with early respiratory distress syndrome.
Retinal Vein Occlusion
Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Rhinitis, Allergic
Increased Thrombin-Activatable Fibrinolysis Inhibitor in Response to Sublingual Immunotherapy for Allergic Rhinitis.
Sepsis
Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats.
Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.
Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis.
ST Elevation Myocardial Infarction
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Stomach Neoplasms
Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer.
Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
Stroke
Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
Dose-Response Relationship Between Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) and Stroke: A Chinese Case-Control Study.
Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke.
Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome.
Thrombin activatable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian-Indian population but may not be a risk for stroke.
Stroke, Lacunar
Evaluation of platelet activation, coagulation, and fibrinolytic activation in patients with symptomatic lacunar stroke.
Thrombocytopenia
In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.
Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.
Thrombocytosis
Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis.
Thromboembolism
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism.
Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Thrombophilia
Hemostasis in Overt and Subclinical Hyperthyroidism.
Preeclampsia and its interaction with common variants in thrombophilia genes.
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor.
Thromboembolism--an important manifestation of inflammatory bowel disease.
Thrombosis
A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity.
Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection.
Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation.
Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor.
Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome.
Fibrinolysis and the risk of venous and arterial thrombosis.
Genetic Polymorphisms Associated with Thrombotic Disease Comparison of Two Territories: Myocardial Infarction and Ischemic Stroke.
Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
Inside the Thrombus: Association of Hemostatic Parameters With Outcomes in Large Vessel Stroke Patients.
Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).
Levels of thrombin-activatable fibrinolysis inhibitor and platelet-activating factor in recurrent pregnancy loss patients.
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.
Measuring fibrinolysis: from research to routine diagnostic assays.
Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis.
Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor.
Plasma carboxypeptidases as regulators of the plasminogen system.
Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Reduced thrombin activatable fibrinolysis inhibitor and enhanced inflammatory markers in ACS.
Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia.
TAFIa inhibitors in the treatment of thrombosis.
TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
The Crystal Structure of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Provides the Structural Basis for Its Intrinsic Activity and the Short Half-life of TAFIa.
The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behçet disease and their association with thrombosis.
The Prothrombotic State Associated with SARS-CoV-2 Infection: Pathophysiological Aspects.
The role of thrombin activatable fibrinolysis inhibitor (TAFI) in arterial thrombosis at young age: the ATTAC study.
Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs.
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Thrombotic Microangiopathies
Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Thyroid Nodule
Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
Venous Thromboembolism
Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism.
Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism.
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.
[Correlation analysis of Thrombin-activatable Fibrinolysis Inhibitor Single Nucleotide Polymorphism with Venous Thromboembolism].
Venous Thrombosis
Association between thrombin-activatable fibrinolysis inhibitor gene polymorphisms and venous thrombosis risk: a meta-analysis.
Changes in ADMA and TAFI levels after stenting in coronary artery disease patients.
Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.
Fibrinolysis and the risk of venous and arterial thrombosis.
Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems.
S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism.
Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis.
The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
Thrombin-Activatable Fibrinolysis Inhibitor Polymorphisms and Cerebral Venous Thrombosis in Mexican Mestizo Patients.
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
von Willebrand Diseases
Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.
Yersinia Infections
Protective Roles for Fibrin, Tissue Factor, Plasminogen Activator Inhibitor-1, and Thrombin Activatable Fibrinolysis Inhibitor, but Not Factor XI, during Defense against the Gram-Negative Bacterium Yersinia enterocolitica.